NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee.
Welcome to the Healthcare Insights Desk at TheUnplanned.in, where we delve deep into the world of health and wellness. Our dedicated team of writers brings you authoritative articles, expert opinions, and insightful analyses on all facets of healthcare.
